Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 3Other solid neoplasm 3Dermatologic 3Gynecologic 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Classical hematology 1

Conditions

Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Head and Neck Neoplasms 1

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Semaxinib × Dermatologic × Clear all
NCT00017316 2013-02-11

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled
Dermatologic

Melanoma

NCT00006003 2013-01-24

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Dermatologic

Melanoma

NCT00006361 2009-12-04

SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡